Deramiocel FDA Decision: Capricor Trims Staff as Nov 22 DMD Verdict Nears
Capricor cut about 10% of staff and is preparing a solo launch ahead of the November 22 FDA decision on deramiocel for Duchenne muscular dystrophy.
Tag: Capricor Therapeutics
Read More